Results 41 to 50 of about 7,047 (156)

Palmitoyl Acyltransferase Zdhhc17 Promotes Functional Recovery After Spinal Cord Injury by Targeting the Nuclear Transport Factors Kpna2 and Ipo9

Advanced Science, EarlyView.
In this study, we demonstrate that Zdhhc17, acting as a PAT, suppresses neuronal apoptosis and promotes axon regeneration after injury, thereby enhancing functional recovery following SCI. In this context, Kpna2 and Ipo9 serve as novel palmitoylation substrates of Zdhhc17, whose palmitoylation prevents the injury‐induced degradation of their proteins ...
Meixuan Chen, Huan Chen, Sining Ding, Fan Liu, Xiaofei Zheng, Yuan Wang, Ruitu Tian, Huan Li, Peilin Liu, Le Hu, Bin Liu, Limin Rong, Mangmang Li   +12 more
wiley   +1 more source

Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

American Journal of Hematology, EarlyView.
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac, Audrey Bidet, Elise Chapiro, Nathalie Douet‐Guilbert, Jean‐Baptiste Gaillard, Nada Assaf, Nathalie Auger, Hend Chaker, Jasmine Chauzeix, Inge Govaerts, Hippolyte Guérineau, Christine Lefebvre, Pauline Roynard, Hélène Guermouche, Lucienne Michaux, Marie‐Bérengère Troadec, Lauren Véronèse   +16 more
wiley   +1 more source

CRISPR-Cas9 Screening of Kaposi’s Sarcoma-Associated Herpesvirus-Transformed Cells Identifies XPO1 as a Vulnerable Target of Cancer Cells

mBio, 2019
The abnormal proliferation of cancer cells is driven by deregulated oncogenes or tumor suppressors, among which the cancer-vulnerable genes are attractive therapeutic targets.
Marion Gruffaz, Hongfeng Yuan, Wen Meng, Hui Liu, Sangsu Bae, Jin-Soo Kim, Chun Lu, Yufei Huang, Shou-Jiang Gao   +8 more
doaj   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

Viruses with pharmacologic evidence of XPO1 (CRM1)-dependence.

, 2023
Viruses with pharmacologic evidence of XPO1 (CRM1)-dependence.
Mahmoud Shehata (9574695), David Olagnier (205583), Andreas Pavlou (15272395), Ulrich Martin (62121), Stephan Pleschka (85578), Fabio Begnini (4795374), Anna K. H. Hirsch (7491110), Naziia Kurmasheva (11575748), Sylvia Merkert (16558010), Ruth Olmer (3744291), Thomas B. Poulsen (2478502), Anders E. Kiib (16558004), Chutao Chen (16558007), Fakhar H. Waqas (16557998), Walid A. M. Elgaher (8355894), Antoine Lacour (16558001), Frank Pessler (52000), Julia Dahlmann (4919113)   +17 more
core   +1 more source

Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma

British Journal of Haematology, EarlyView.
In patients with lenalidomide‐refractory multiple myeloma from the BOSTON trial subgroup analysis,1 selinexor (SEL) dose reduction versus full dosing substantially improved efficacy outcomes, including higher overall response rate (74.3% vs. 55.6%), deeper responses (≥ very good partial response: 48.6% vs.
Muhamed Baljevic
wiley   +1 more source

Selinexor and COVID-19: The Neglected Warden

Frontiers in Pharmacology, 2022
A novel severe acute respiratory distress syndrome coronavirus type 2 (SARS-CoV-2) has been confirmed as the cause of the global pandemic coronavirus disease 2019 (COVID-19).
Gomaa Mostafa-Hedeab, Gomaa Mostafa-Hedeab, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Nermeen N. Welson, Gaber El-Saber Batiha, Carlos Adam Conte-Junior   +6 more
doaj   +1 more source

Cytology‐First Diagnostic Workflow for Melanoma of Unknown Primary With Molecular Profiling

Cytopathology, EarlyView.
Cytology‑first diagnostic workflow for melanoma of unknown primary. Fine‑needle aspiration of an enlarged lymph node enables rapid cytologic evaluation and immunocytochemical confirmation of melanocytic lineage (SOX10). This early cytologic diagnosis facilitates timely surgical excision and comprehensive genomic profiling, supporting integrated ...
Hong Yu, Mokhtar Abdelhammed, Xu Cao, Nisha S. Ramani   +3 more
wiley   +1 more source

Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling

, 2023
Acute myeloid leukemia (AML) is a high-mortality malignancy with poor outcomes. Azacitidine induces cell death and demonstrates treatment effectiveness against AML.
Huideng Long, Jun Li, Zheng Ge, Yue Hou, Chunhua Song   +4 more
core   +1 more source

Reversible disruption of XPO1-mediated nuclear export inhibits respiratory syncytial virus (RSV) replication

Scientific Reports, 2021
Respiratory syncytial virus (RSV) is the primary cause of serious lower respiratory tract disease in infants, young children, the elderly and immunocompromised individuals.
Cynthia Mathew, Sharon Tamir, Ralph A. Tripp, Reena Ghildyal   +3 more
doaj   +1 more source